- PA5-29846 - Invitrogen Antibodies TPM1 antibody

Shen S, Sewanan LR, Shao S, Halder SS, Stankey P, Li X, Campbell SG
Stem cell reports 2022 Sep 13;17(9):2037-2049

Lin J, Shen J, Yue H, Cao Z
Oncology reports 2019 Dec;42(6):2371-2381

No comments: Submit comment

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: TPM1 Polyclonal Antibody detects Tropomyosin 1 protein at cytoskeleton by immunofluorescent analysis. Sample: HeLa cells were fixed in 4% paraformaldehyde at RT for 15 min. Green: Tropomyosin 1 stained by TPM1 Polyclonal Antibody (Product # PA5-29846) diluted at 1:500. Blue: Fluoroshield with DAPI . Scale bar= 10 µm.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunofluorescence analysis of TPM1 was performed using 70% confluent log phase HSkMs cells. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 15 minutes, and blocked with 1% BSA for 1 hour at room temperature. The cells were labeled with TPM1 Rabbit Polyclonal Antibody (Product # PA5-29846) at 5 microgram/mL in 0.1% BSA, incubated at 4 degree Celsius overnight and then labeled with Goat anti-Rabbit IgG (H+L) Superclonal™ Secondary Antibody, Alexa Fluor® 488 conjugate (Product # A27034) at a dilution of 1:2000 for 45 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with ProLong™ Diamond Antifade Mountant with DAPI (Product # P36962). F-actin (Panel c: red) was stained with Rhodamine Phalloidin (Product # R415). Panel d represents the merged image showing Cytoskeletal localization. Panel e represents control cells with no primary antibody to assess background. The images were captured at 60X magnification.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1. Expression of miR-183-5p.1 and TPM1 in GC cells and tissues. miR-183-5p.1 levels in (A) normal tissues, adjacent tissues, GC tissues and (B) normal gastric epithelial cells (GES-1) and GC cell lines (MKN-7, AGS, HGC-27) were determined by RT-qPCR. TPM1 mRNA expression in (C) normal tissues, adjacent tissues, GC tissues and (D) GES-1, MKN-7, AGS, HGC-27 cells as quantified by RT-qPCR. (E) TPM1 protein expression in GES-1 and AGS cells was determined by western blotting and (H) statistically analyzed. (F) TPM1 protein expression in GES-1 and MKN-7 cells was determined by western blotting and (I) statistically analyzed. (G) TPM1 protein expression in GES-1 and HGC-27 cells was determined by western blotting and (J) statistically analyzed. Results are presented as the mean +- standard error of the mean (n=3) *P

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3. Experimental validation of miR-183-5p.1 as a TPM1 regulator. (A) miR-183-5p.1 binding with the 3'UTR of TPM1 predicted by TargetScan and coding sequence of miR-183-5p.1 and TPM1. The luciferase activities of WT-TPM1 mRNAs in GC (B) AGS and (J) HGC-27 cells were significantly enhanced by transfection with miR-183-5p.1 inhibitors and markedly decreased in (F) AGS and (O) HGC-27 cells by miR-183-5p.1 mimics following the Luciferase reporter assay. TPM1 expression was markedly increased in (C-E) AGS and (K-N) HGC-27 cells by miR-183-5p.1 inhibitors and significantly decreased in (G-I) AGS and (P-R) HGC-27 cells by miR-183-5p.1 mimics as revealed by reverse transcription-quantitative PCR and western blotting. GAPDH served as the internal control. Results are presented as the mean +- standard error of the mean (n=3). *P

PA5-29846